We are cultivating a growing pipeline of research programs and potential drug candidates derived from the Pardes chemistry platform.
- Discovery Disc.
- Ind Enabling
- Phase 1
- MID 2022*
Phase I Data 1Q22*
Next Gen Coronavirus
- Lead Optimization/ Preclinical
- 2H 2022*
INFORMATION ON PBI-0451
PBI-0451, an Investigational Coronaviral Protease Inhibitor
We are building a pipeline of potential drug candidates for a variety of disease targets and therapeutic categories. Initially, our goal is to become a global leader in the treatment and prevention of coronavirus infections. We believe that a safe, oral, coronaviral protease inhibitor, rapidly deployed, could be instrumental in helping to end the ongoing COVID-19 pandemic and preventing the next.
Our lead product candidate, PBI-0451, has been evaluated in pre-clinical in vitro models and has shown activity against multiple coronaviruses, including SARS-CoV-2 and variants of concern such as Delta, other human coronaviruses of pandemic potential (SARS, MERS), as well as common cold related coronavirus strains (OC43, 229E). PBI-0451 is currently being studied in a blinded, randomized, and placebo-controlled dose-escalation Phase 1 clinical trial enrolling 180 healthy adult volunteers at a leading clinical research center in New Zealand.
TARGETING VIRAL MAIN PROTEASE (Mpro)
Blocking Replication Before It Begins
Over the last 40 years, significant progress has been made in our understanding of how viruses infect cells, replicate, and spread within the body. We believe a promising method for treating and preventing coronaviral infections is to target the Viral Main Protease (Mpro), a highly conserved protein required for the earliest stages of coronavirus replication. Blocking this target blocks the virus’ ability to replicate. We believe the highly conserved nature of Mpro across multiple coronaviruses, including SARS, MERS, and emerging SARS-CoV-2 variants of concern, supports the potential of this target for both existing and future coronaviruses. These insights led to the design of PBI-0451, a coronaviral Mpro inhibitor with demonstrated in vitro activity against multiple strains of coronaviruses. PBI-0451 is currently being evaluated in a Phase I clinical trial.